Back

Obigen Pharma advances OBI-858 trials, targets Taiwan launch in 2028

Verifying
  • Obigen Pharma advanced Taiwan and U.S. clinical development for its OBI-858 botulinum toxin.
  • The repeat-dosing study recorded a 0.7% drug-related adverse-event rate across 432 treatment sessions.
  • Obigen plans Taiwan approval and commercial launch in the first half of 2028.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.